Trial Profile
A Study to Evaluate the Clinical Significance of Circulating CD33, CD11b, HLA-DR- MDSCS as Prognostic and Predictive Biomarkers of Response and Overall-Survival in Stage IV Melanoma Patients Treated With Ipilimumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 20 May 2016 New trial record
- 13 May 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research